Published • loading... • Updated
Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
Summary by psychedelicalpha.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
Psychedelics Beyond MAHA? • What ICER’s Spravato Review Might Mean for Compass’ Psilocybin • Judge Dismisses DemeRx’s Ibogaine Suit Against atai, for Now • FDA Updates House Caucus on Psychedelics, Clarifies Limits of SPAs • Judge Sends Terran’s Trade Secrets Suit Against Compass to Trial • Half of Registered Spravato Sites Treated Patients in Past Six Months • Jocasta Options Diamond’s Non-Hallucinogenic 5-HT2A Agonists • Usona Surprises Some; …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
